March 1, 2023
FDA has been conducting applied research on pharmacodynamic (PD) biomarkers to help facilitate
biosimilar product development
- Have any questions?
- +1-888-INTL-SOS
- support@globalreachhealth.com
GlobalReach Health
March 1, 2023
In March 2023, the three major insulin manufacturers (Eli Lilly, Novo Nordisk, and Sanofi) reduced the
list prices of several brand insulins, effective in 4Q 2023 (Lilly)
March 1, 2023
March 1, 2023 - Eli Lilly announced the price of Rezvoglar (insulin glargine-aglr) as well as price cuts on
other insulin products and a cap on out-of-pocket (OOP) costs for insulin.
February 28, 2023
February 28, 2023 – Reata Pharmaceuticals, Inc., a biopharmaceutical company focused on developing
and commercializing novel therapies for patients with severe diseases
February 23, 2023
February 23, 2023 - Global Pharma Healthcare is voluntarily recalling Batch No. H29 of Artificial Eye
Ointment, distributed by Delsam Pharma
February 23, 2023
February 23, 2023 – The FDA has approved AltuviiioTM (Sanofi) [Antihemophilic Factor (Recombinant), Fc-
VWF-XTEN Fusion Protein-ehtl], previously referred to as efanesoctocog
February 22, 2023
February 22, 2023 - Pfizer Inc. has announced that the U.S. Food and Drug Administration has granted
Priority Review for the company’s Biologics License Application (BLA) for elranatamab
February 21, 2023
February 21, 2023 - Regeneron Pharmaceuticals, Inc. has announced the U.S. Food and Drug
Administration has accepted for Priority Review the Biologics License